In conclusion, this is the first study based on STMs to predict the molecular features of EGFR‐mutated lung cancer during the targeted therapy, including clearance of targeted EGFR ctDNA and the emergence of secondary EGFR T790M. This evidence concerns the gene EGFR and lung cancer.